Meeting
2024 ASCO Annual Meeting
Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.
Authors
Andy Cheng
Royal Free London NHS Foundation Trust, London, United Kingdom
Andy Cheng , Suzanne Frank , Katherine Baines , Mark Nathan , Rosalie V. Douglas , Rushan Sylva , Jessica Ball , Constantinos Savva , Thomas Talbot , Olga Oikonomidou , Jenny Smith , Alastair Thomson , Felicity Ross , Apostolos Konstantis , Nicola Ainsworth , Pietro Luciano , Pooja Iyer , Shyamika Acharige , Shaikh Rana , Judy King
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1024)
DOI
10.1200/JCO.2024.42.16_suppl.1024
Abstract #
1024
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.
First Author: Carey K. Anders
Poster
2022 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
First Author: Sara A. Hurvitz
Poster
2020 ASCO Virtual Scientific Program
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer.
First Author: Dongmei Ji
Poster
2020 ASCO Virtual Scientific Program
Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
First Author: Hossein Borghaei